INS and Hyperglycemia: STZ administration is well described, reproducible model of type 1 diabetes, manifested by insulitis, reduction in insulin secretion capacity, and hyperglycemia, although due to its development in the absence of T- and B cell-contribution not perfectly resembles autoimmune human condition [18].